Sort by

Send to

Choose Destination

Search results

Items: 5


The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.

Rafiei A, Mian AA, Döring C, Metodieva A, Oancea C, Thalheimer FB, Hansmann ML, Ottmann OG, Ruthardt M.

PLoS Genet. 2015 Apr 28;11(4):e1005144. doi: 10.1371/journal.pgen.1005144. eCollection 2015 Apr.


PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, Metodieva A, Stroganov O, Novikov F, Brill B, Chilov G, Hoelzer D, Ottmann OG, Ruthardt M.

Leukemia. 2015 May;29(5):1104-14. doi: 10.1038/leu.2014.326. Epub 2014 Nov 14.


Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.

Khateb M, Ruimi N, Khamisie H, Najajreh Y, Mian A, Metodieva A, Ruthardt M, Mahajna J.

BMC Cancer. 2012 Nov 27;12:563. doi: 10.1186/1471-2407-12-563.


Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.

Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M.

BMC Cancer. 2012 Sep 17;12:411. doi: 10.1186/1471-2407-12-411.


p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M.

Haematologica. 2012 Feb;97(2):251-7. doi: 10.3324/haematol.2011.047191. Epub 2011 Nov 4.

Supplemental Content

Loading ...
Support Center